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Introduction
Despite intense ongoing asthma research, there is cur-
rently an epidemic of this disease in the western world
and the incidence is on the rise (1, 2). Experimentation
in the asthma field has largely focused on analysis of the
cellular and molecular events induced by allergen expo-
sure in sensitized animals (primarily mice) and humans.
These studies have identified elevated production of
IgE, mucus hypersecretion, airway obstruction, inflam-
mation, and enhanced bronchial reactivity to spasmo-
gens in the asthmatic response (3–5). Clinical and exper-
imental investigations have demonstrated a strong
correlation between the presence of CD4+ Th2 cells and
disease severity, suggesting an integral role for these
cells in the pathophysiology of asthma (6). Th2 cells are
thought to induce asthma through the secretion of an
array of cytokines (IL-4, -5, -6, -9 -10, -13, and -25) that
activate inflammatory and residential effector pathways
both directly and indirectly (7, 8). In particular, IL-4 and
IL-13 are produced at elevated levels in the asthmatic
lung and are thought to be central regulators of many
of the hallmark features of disease (9, 10). Although
these studies have provided the rationale for the devel-
opment of multiple therapeutic agents that interfere
with specific inflammatory pathways (11), the develop-
ment of the asthma phenotype is likely to be related to
the complex interplay of a large number of additional
genes and their polymorphic variants. Accordingly, we
aimed to identify new genes involved in the pathogene-
sis of experimental asthma with the use of an empirical
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Asthma is on the rise despite intense, ongoing research underscoring the need for new scientific
inquiry. In an effort to provide unbiased insight into disease pathogenesis, we took an approach involv-
ing expression profiling of lung tissue from mice with experimental asthma. Employing asthma mod-
els induced by different allergens and protocols, we identified 6.5% of the tested genome whose expres-
sion was altered in an asthmatic lung. Notably, two phenotypically similar models of experimental
asthma were shown to have distinct transcript profiles. Genes related to metabolism of basic amino
acids, specifically the cationic amino acid transporter 2, arginase I, and arginase II, were particularly
prominent among the asthma signature genes. In situ hybridization demonstrated marked staining
of arginase I, predominantly in submucosal inflammatory lesions. Arginase activity was increased in
allergen-challenged lungs, as demonstrated by increased enzyme activity, and increased levels of
putrescine, a downstream product. Lung arginase activity and mRNA expression were strongly induced
by IL-4 and IL-13, and were differentially dependent on signal transducer and activator of transcrip-
tion 6. Analysis of patients with asthma supported the importance of this pathway in human disease.
Based on the ability of arginase to regulate generation of NO, polyamines, and collagen, these results
provide a basis for pharmacologically targeting arginine metabolism in allergic disorders.
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approach that uses DNA microarray analysis of whole
lung RNA. By using two phenotypically similar models
of experimental asthma induced by independent
regimes, we report distinct transcript profiles associat-
ed with each model. Among the asthma signature genes,
we found concerted overexpression of the genes encod-
ing for molecules involved in uptake and metabolism of
basic amino acids (e.g., arginine), specifically, arginine
metabolism by arginase. We chose to focus on these
genes because intracellular arginine is a regulator of
diverse pathways, including production of NO,
polyamines, and proline; these molecules regulate crit-
ical processes associated with asthma, including airway
tone, cell hyperplasia, and collagen deposition, respec-
tively (12, 13). Our results demonstrate specific regula-
tion of arginase by diverse allergens, IL-4, and IL-13. In
addition, we demonstrate overproduction of an
arginase downstream product in the asthmatic lung.
Finally, we provide evidence that this pathway is opera-
tional in human asthma.
Methods
Experimental asthma induction. Balb/c mice were
obtained from the National Cancer Institute (Freder-
ick, Maryland, USA) and signal transducer and activa-
tor of transcription 6–deficient (STAT6-deficient) mice
(Balb/c) were obtained from Jackson Laboratory (Bar
Harbor, Maine, USA); all mice were housed under spe-
cific pathogen-free conditions. Asthma models were
induced by intraperitoneal injection with 100 µg OVA
(grade V, Sigma-Aldrich, St. Louis, Missouri, USA) and
1 mg aluminum hydroxide (alum) as adjuvant twice,
followed by two 50 µg OVA or saline intranasal chal-
lenges 3 days apart, starting a least 10 days after the
second sensitization, as previously described (14). The
level of LPS in OVA was less than 2 pg/ml as detected
by the Limulus assay. Mice were killed 3 or 18 hours
after the first or second challenge. Aspergillus fumigatus
antigen-associated asthma was induced by challenging
mice intranasally three times a week for 3 weeks, as
described (14–16). In brief, mice were lightly anes-
thetized with isofluorane inhalation and 100 µg (50
µl) of A. fumigatus extract (Bayer Pharmaceuticals,
Spokane, Washington, USA) or 50 µl of normal saline
solution alone was applied to the nasal cavity by using
a micropipette with the mouse held in the supine posi-
tion. After instillation, mice were held upright until
alert. Mice were killed 18 hours after the last challenge.
This protocol induces a similar phenotype to the OVA
model (characterized by eosinophilia, Th2 responses,
eotaxin-1 and eotaxin-2 induction, and airway hyper-
reactivity) (refs. 14–17, and data not shown).
Preparation of RNA and microarray hybridization. RNA
was extracted by using the Trizol reagent as per the man-
ufacturer’s instructions. After Trizol purification, RNA
was repurified with phenol-chloroform extraction and
ethanol precipitation. Microarray hybridization was per-
formed by the Affymetrix Gene Chip Core facility at
Cincinnati Children’s Hospital Medical Center. Briefly,
RNA quality was first assessed by using the Agilent bio-
analyzer (Agilent Technologies, Palo Alto, California,
USA) and only those samples with 28S/18S ratios
between 1.3 and 2 were subsequently used. RNA was
converted to cDNA with Superscript choice for cDNA
synthesis (Invitrogen, Carlsbad, California, USA) and
subsequently converted to biotinylated cRNA with Enzo
High Yield RNA Transcript labeling kit (Enzo Diagnos-
tics, Farmingdale, New York, USA). After hybridization
to the murine U74Av2 GeneChip (Affymetrix, Santa
Clara, California, USA), the gene chips were automati-
cally washed and stained with streptavidin-phycoery-
thrin by using a fluidics system. The chips were scanned
with a Hewlett-Packard GeneArray Scanner (Hewlett-
Packard, Palo Alto, California, USA). This analysis was
performed with one mouse per chip (n = 3 or more for
each allergen challenge condition and n = 2 or more for
each saline challenge condition). A further description
of the methodology, according to MIAME (Minimum
Information About a Microarray Experiment) guidelines
(www.mged.org/Workgroups/MIAME/miame.html) is
provided in supplementary information (http://www.jci.
org/cgi/content/full/111/12/1863/DC1).
Microarray data analysis. From data image files, gene
transcript levels were determined with the use of algo-
rithms in the Microarray Analysis Suite software
(Affymetrix). Global scaling was performed to compare
genes from chip to chip; thus, each chip was normal-
ized to an arbitrary value (1500). Each gene is typically
represented by a probe set of 16 to 20 probe pairs. Each
probe pair consists of a perfect match oligonucleotide
and a mismatch oligonucleotide that contains a one-
base mismatch at a central position. Two measures of
gene expression were used, absolute call and average
difference. Absolute call is a qualitative measure in
which each gene is assigned a call of present, marginal,
or absent, based on the hybridization of the RNA to the
probe set. Average difference is a quantitative measure
of the level of gene expression, calculated by taking the
difference between mismatch and perfect match of
every probe pair and averaging the differences over the
entire probe set. Differences between saline- and aller-
gen-treated mice were also determined with the use of
the GeneSpring software (Silicon Genetics, Redwood
City, California, USA). Data were normalized to the
average of the saline-treated mice. Gene lists were cre-
ated that contained genes with P < 0.05 and greater
than twofold change by log transformation of average
difference values (by using genes that received a pres-
ent call, which was based on the hybridization signal).
Excel files (Microsoft, Redmond, Washington, USA)
that include average differences and absolute call val-
ues for all 12,422 genes in the 11 analyzed DNA chips
are presented in supplementary Table 1 (http://www.jci.
org/cgi/content/full/111/12/1863/DC1).
Northern blot and RT-PCR analysis. RNA was extracted
from the lungs of wild-type Balb/c mice, IL-4 Clara cell
10 lung transgenic mice (18) containing wild-type or
deleted copies of the gene for STAT6 (all in the Balb/c
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background) (19), and from the lungs of mice treated
with intranasal or intratracheal saline or recombinant
murine IL-13 (obtained from Debra Donaldson, Wyeth
Research, Madison, New Jersey, USA), as previously
reported (17, 20, 21). The cDNA probes, generated by
PCR or from commercially available vectors (Image
Consortium obtained from American Tissue Culture
Collection, Rockville, Maryland, USA, or Incyte
Genomics, Palo Alto, California, USA), were sequence
confirmed, radiolabeled with 32P, and hybridized by
using standard conditions. RT-PCR, which used stan-
dard procedures with gene specific primers, was per-
formed by using lung cDNA as a template.
In situ hybridization of mouse lung. In situ hybridization
was performed as described (22). In brief, murine
arginase I cDNA in plasmid pCMV-SPORT6 (Incyte
Genomics, St. Louis, Missouri, USA) was linearized by
EcoRI or Not I digestion, and antisense and sense RNA
probes, respectively, were generated by T7 and SP6
RNA polymerase (Riboprobe Gemini Core System II
transcription kit; Promega, Madison, Wisconsin, USA).
The radiolabeled (αS35-UTP) probes were hybridized
and washed under high-stringency conditions.
Immunohistochemistry. Slides from saline- and OVA-chal-
lenged lung tissue were stained with the anti–arginase-I
antibody (affinity-purified RG-1, kindly provided by Sid-
ney Morris, University of Pittsburgh School of Medicine)
(23) at 3.5 µg/ml. After staining with a biotinylated anti-
chicken secondary antibody at 15 µg/ml (Vector Labora-
tories Inc., Burlingame, California, USA) and strepta-
vidin-Vectastain Elite ABC-peroxidase reagents (Vector
Laboratories Inc.), slides were subsequently developed
with diaminobenzidine (DAB) (Vector Laboratories Inc.).
Anti-Mac-3 staining (10 µg/ml; BD Pharmingen, San
Diego, California, USA) was performed with the Vectas-
tain Elite ABC-Peroxidase Rat IgG kit for detection,
according to the manufacturer’s instructions. As negative
controls, tissues were stained without primary antibody.
Arginase activity. Arginase activity was measured by
using the blood urea nitrogen reagent (Sigma-Aldrich,
St. Louis, Missouri, USA) according to established tech-
niques (23–25). In some experiments, arginase activity
was measured in the J774A.1 macrophage cell line
(ATCC), plated at 0.25 × 106/ml and stimulated with
0.5–50 ng/ml IL-13 for 18 hours. Arginase activity was
measured in cell lysates, as described above.
Putrescine levels. After acid extraction, putrescine con-
tent was determined by ion-pair reverse-phase HPLC,
by using methods previously described (26).
Analysis of human lung samples. Fiberoptic bron-
choscopy and endobronchial biopsy of the subseg-
mental bronchus of allergic asthmatics and healthy
controls after their informed consent was conducted,
by using methods previously reported (27, 28). Asth-
matic patients (age range 27–44 years, 75% male) were
all atopic individuals requiring intermittent β2-agonist
therapy (forced expiratory volume in 1 s [FEV1] values
of 78%–90% normal), not requiring inhaled glucocorti-
coids for at least 4 weeks, free of respiratory infections
for at least 8 weeks, and not on immunotherapy for at
least the last 4 years. Healthy, gender-matched controls
(age range 29–44) were nonatopic and had FEV1 values
greater than 95% normal. Bronchoalveolar lavage cells
after cytocentrifugation (after methanol/acetone fixa-
tion) were immunohistochemically stained with mon-
oclonal mouse IgG1 antihuman arginase I (BD Bio-
sciences, Lexington, Kentucky, USA) by using 1/100
dilution. The slides were developed in Fast Red (Sigma-
Aldrich) in the presence of levamisole, as described pre-
viously (29). For negative control preparations, the pri-
mary antibody was replaced by saline solution or
nonimmune mouse IgG1. A minimum of 1000 cells on
blindly coded cytospin slides were scored for the num-
ber of positive cells, expressed as a percentage of total
cells. In situ hybridization of lung samples from asth-
matic and control individuals was performed with
radiolabeled [αS35-UTP] sense and antisense probes
hybridized and washed under high-stringency condi-
tions, as previously described (28).
Statistical analysis. The significance of differences
between the means of experimental groups was ana-
lyzed with Student unpaired t test. Values were report-
ed as the mean ± SD. Differences in mean values were
considered significant if P < 0.05.
Results
DNA microarray analysis identifies a subset of the genome
involved in asthma pathogenesis. We were first interested in
reproducibly and accurately identifying genes that were
differentially expressed in a well-established model of
asthma. To accomplish this aim, mice were intraperi-
toneally sensitized with the allergen OVA in the pres-
ence of the adjuvant alum and subsequently challenged
intranasally with OVA or control saline on two occa-
sions separated by 3 days. Eighteen hours after the last
allergen challenge, one lobe of the lung was subjected to
histologic analysis and the remainder of the lung was
used for RNA analysis. As expected, histologic analysis
revealed that the allergen-challenged mice had a marked
eosinophil-rich inflammatory response, as previously
reported (30). To verify the presence of allergen-induced
mRNA transcripts, the RNA was subjected to Northern
blot analysis to analyze the induction of the chemokine
eotaxin-1, which has previously been shown to be sig-
nificantly induced by allergen challenge (30). The find-
ing that the allergen-challenged lungs had abundant
eotaxin-1 mRNA levels, whereas saline-treated mice had
very low levels, validated the experimental induction
protocol (Figure 1a). We next subjected the RNA to
microarray analysis by using the Affymetrix chip
U74Av2 that contains oligonucleotide probe sets repre-
senting 12,422 genetic elements, the largest collection
of characterized mouse genes commercially available.
Comparison of the two saline-challenged mice to each
other and comparison of the two allergen-challenged
mice to each other revealed 1% or less of the genes
changing more than twofold. Analysis of present genes
in a scatter plot revealed relatively few points outside of
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the twofold boundaries (Figure 1b). In contrast, pair-
wise comparison of allergen-challenged mice to saline-
challenged mice revealed a greater than twofold change
in 6.5% ± 0.8% of the genes (Figure 1c). A full list of the
OVA-induced genes is presented in supplementary
Table 2 (http://www.jci.org/cgi/content/full/111/12/
1863/DC1). Importantly, eotaxin-1 was reproducibly
identified in the allergen-induced genes (Figure 1d).
Quantitative analysis of the average difference signal for
eotaxin-1 between allergen and saline revealed a 25-fold
induction (P = 0.001). Collectively, these data illustrat-
ed the potential value of the scientific approach; thus,
providing the impetus for the next set of experiments.
We aimed to determine the degree of overlap between
allergen-induced global transcript profiles in two inde-
pendent models of asthma. We analyzed experimental
asthma induced by A. fumigatus antigen because this
model involves a unique mucosal sensitization route
(intranasal) compared with the OVA model (31) and
because A. fumigatus is a ubiquitous and common aeroal-
lergen. Importantly, both asthma models have similar
phenotypes, including Th2-associated eosinophilic
inflammation, mucus production, and airway hyperre-
sponsiveness (AHR) (14–16). Lung RNA was obtained
18 hours after nine doses of intranasal A. fumigatus
allergen or saline challenges (delivered over the course
of 3 weeks). We compared allergen-challenged mice
(OVA or Aspergillus) with their respective saline control
mice, and genes were identified that statistically
increased (P < 0.05) at least twofold after allergen chal-
lenge. Compared with mice challenged with saline,
OVA-challenged mice had 496 genes induced and A.
fumigatus–challenged mice had 527 genes induced (Fig-
ure 1e). A full list of A. fumigatus antigen-induced genes
and the overlap with the OVA-induced genes are pre-
sented in supplementary Tables 3 and 4, respectively
(http://www.jci.org/cgi/content/full/111/12/1863/
DC1). Notably, the majority (59% of OVA and 55% of
Aspergillus) of the induced transcripts overlapped
between the two experimental asthma models (Figure
1e); however, there was a large subset of the identified
genome specific to each model, indicating that
although experimental asthma models have similar
apparent phenotypes, there is large genetic diversity, as
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Figure 1
Microarray analysis of experimental asthma. In a, the induction of eotaxin-1 in allergen-challenged mice as measured by Northern blot analy-
sis is shown. Total RNA (10 µg) was electrophoresed, transferred, and hybridized with a radiolabeled eotaxin-1 cDNA probe. The location
of 18S RNA is shown. Each lane represents a separate mouse. Ethidium bromide (EtBr) staining of the RNA gel is also shown. In b, scatter
plots of the average difference of present genes in two representative saline-challenged (left) or OVA-challenged (right) samples are shown.
In c, the average difference of present genes in a representative saline-treated sample compared with a representative OVA-treated sample
is shown. In d, quantitative analysis of the eotaxin-1 signal for saline- and OVA-treated mice is shown (n = 3 mice each). Error bars repre-
sent the SD. In e, the number of genes increased in experimental asthma induced with OVA or A. fumigatus antigen is depicted in a Venn dia-
gram. Data are derived from statistically significant bioinformatic analysis as described in the Methods section. Data are available in sup-
plementary Tables 1–4 (http://www.jci.org/cgi/content/full/111/12/1863/DC1).
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assessed by transcript profiles. This has important
implications in understanding the diverse spectrum of
genes potentially involved in human asthma.
Experimental asthma is associated with induction of genes
involved in L-arginine metabolism. Our results identified
a set of 291 genes that were commonly involved in dis-
ease pathogenesis rather than unique to a particular
allergen or mode of disease induction (Figure 1e).
These “asthma signature” genes provide a valuable
opportunity to define new pathways involved in the
pathogenesis of allergic airway inflammation. In this
regard, we were struck by the high level of transcripts
for genes involved in metabolism of L-arginine.
Arginase I, arginase II, and the L-arginine transporter,
cationic amino acid transporter (CAT)2, were strong-
ly induced (Figure 2, a–c). We were particularly sur-
prised to find induction of genes previously thought
to be primarily involved in metabolic pathways in the
liver. Other enzymes involved in L-arginine metabo-
lism, such as argininosuccinate synthetase (AS), 
L-ornithine decarboxylase (L-ODC), and L-ornithine
aminotransferase (L-OAT) were not significantly dif-
ferent between saline- and allergen-challenged mice
(Figure 2d and data not shown). Interestingly,
microarray analysis revealed very specific dysregula-
tion of arginase compared with NOS. For example, the
hybridization signals for eNOS and neuronal NOS
were below background in the saline- and allergen-
challenged lung (data not shown). Although the iNOS
mRNA was detectable under most conditions, it did
not change significantly between saline and allergen
challenge (Figure 2e and data not shown).
The enzyme arginase is a urea cycle enzyme that exists
in two isoforms (60% amino acid homology), designat-
ed type I and type II, which are encoded by different
genes on distinct chromosomes (12). Arginase I is a
cytoplasmic protein that is primarily expressed in the
liver; whereas arginase II is a mitochondrial protein
expressed in a variety of tissues, especially the kidney
and prostate (32). The exact function of arginase in
extrahepatic tissue is not well understood. However,
the product of arginase, L-ornithine, is a precursor in
the production of polyamines (e.g., putrescine, spermi-
dine, and spermine) and proline, which control cell
proliferation and collagen production, respectively
(Figure 2d) (12, 32). In fact, increased expression of
arginase I alone is sufficient to increase the prolifera-
tion rates of vascular smooth muscle (24) and endothe-
lial cells (25). Thus, arginase activity is potentially crit-
ically linked to cell growth and connective tissue
production. Notably, both of these processes are key
parameters in the pathogenesis of asthma (33). We sub-
sequently determined by Northern blot analysis that
there was a time- and dose-dependent induction of
arginase I during the progression of OVA-induced
experimental asthma; arginase I was induced 18 hours
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Figure 2
Expression of L-arginine metabolizing enzymes. Expression of arginase I (a), arginase II (b), CAT2 (c), and iNOS (e) in ovalbumin (OVA) and
A. fumigatus (Asp)-challenged mice as measured by gene chip analysis is shown. The average difference for the hybridization signal after saline
(gray bar) and allergen (black bar) challenge is depicted (n = 2 for Aspergillus control group and n = 3 for OVA control group and OVA and
Aspergillus experimental groups). Error bars represent the SD. A schematic representation of the L-arginine metabolism pathway is shown in
d. Genes not present on the chip are depicted with a white box, genes present but not significantly increased with a gray box, and signifi-
cantly increased genes with a black box. Abbreviations are AL, argininosuccinate lyase; AS, argininosuccinate synthetase; ODC, ornithine
decarboxylase; and OAT, ornithine aminotransferase.
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after the first allergen challenge and even higher after
two allergen challenges (Figure 3a). In addition,
although arginase II mRNA induction was weaker than
arginase I, it was induced earlier in the evolution of
experimental asthma (Figure 3a). For example, arginase
II was readily detectable 3 hours after the first allergen
challenge (Figure 3a). The iNOS mRNA was weakly
detectable and was not significantly induced by OVA
challenge (data not shown). In addition, compared
with mice challenged with nine doses of intranasal
saline, A. fumigatus–challenged mice had marked
expression of arginase I and arginase II (Figure 3b).
Consistent with the results in the OVA model, there
were only low levels of induction of iNOS mRNA (data
not shown). Thus, the induction of arginase and CAT2
by allergen challenge was not specific to the antigen
used but appeared to be part of the genetic program of
experimental asthma. We hypothesized that the large
increase in arginase mRNA would be translated into
enhanced arginase activity in the lung because the
activity of arginase is primarily regulated by a tran-
scriptional mechanism (12). Indeed, after induction of
OVA-induced experimental asthma, there was a
marked increase in lung arginase activity (Figure 3c).
Similar results were obtained when asthma was
induced with A. fumigatus antigen; arginase activity was
10.8 ± 10.8 and 357 ± 156 nmol/min/mg protein 
(n = 3–4 mice; P = 0.02) for saline- and A. fumigatus–chal-
lenged mice, respectively. Consistent with the absence
of arginase mRNA in the lung of control mice, the level
of arginase activity in the saline-challenged lung was
close to background. As a control, arginase activity in
the liver was 1522 ± 183 and 1390 ± 78 nmol/min/mg
protein for saline- and OVA-challenged mice, respec-
tively. Finally, in the absence of OVA/alum sensitiza-
tion, two doses of intranasal OVA did not induce
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Figure 3
Northern blot and arginase activity analysis. In a, Northern blot analysis of arginase I and arginase II expression after OVA challenge is shown.
Time points are as follows: 3H = 1 challenge, 3 hours; 18H = 1 challenge, 18 hours; 2C = 2 challenges, 18 hours. The EtBr–stained gel is also
shown. The autoradiograph exposure times were 18 hours and 2 days for arginase I and arginase II, respectively. In b, the expression of arginase
I and arginase II after intranasal challenges with A. fumigatus or saline is shown. Sal, saline; Asp, aspergillus. The autoradiograph exposure times
were 18 hours and 6 days for arginase I and arginase II, respectively. In a and b, each lane represents a separate mouse. In c, arginase activity in
the lungs of saline- and OVA-challenged mice (n = 4 mice and n = 3 mice, respectively) is shown. Arginase activity was measured in lung lysates
with the use of the blood urea nitrogen reagent. As a control, arginase activity in the liver was 1522 ± 183 and 1390 ± 78 nmol/min/mg protein
for saline- and OVA-challenged mice, respectively. In d, putrescine levels in the whole lungs of saline- and OVA-challenged mice (n = 4 mice and n
= 7 mice, respectively) are shown. Putrescine levels were determined by HPLC.
Downloaded from http://www.jci.org on January 21, 2016.   http://dx.doi.org/10.1172/JCI17912
arginase activity (21.4 ± 3.4 and 26.2 ± 4.4 nmol/
min/mg protein [n = 4 mice; P > 0.1] after saline and
OVA, respectively), consistent with the requirement of
an adaptive immune response for arginase induction
rather than a primary innate induction mechanism
(34). Although co-delivery of OVA with different doses
of LPS can have profound effects on OVA-induced
experimental asthma (34), our OVA preparation had
undetectable levels of LPS.
Our results led us to the view that allergic responses
are associated with marked induction of arginine
metabolism via arginase. We were interested in prov-
ing that products downstream from arginase were
actually overproduced in the allergic lung. Recent
studies have shown that arginase is the rate-limiting
enzyme for biosynthesis of putrescine, and that
arginase expression can inhibit cellular apoptosis (35).
We therefore examined putrescine levels in the lungs
of asthmatic and control mice. Examining the whole
lung, we determined that OVA-challenged mice had
significantly increased levels of putrescine (14.7 ± 5.6
vs. 32 ± 13 nmol/g tissue [P < 0.05] in saline and OVA,
respectively, Figure 3d). The twofold increase in
putrescine is remarkable because we are examining
whole lung levels of a mediator with distinct subcellu-
lar localization in the lung (36).
To begin to address the cellular sources of these
molecules, we performed in situ hybridization for
arginase I mRNA. Antisense staining of asthmatic
lung (Figure 4, a and b, and data not shown) revealed
high levels of arginase I in the perivascular and peri-
bronchial pockets of inflammation. No specific stain-
ing with the sense probe in OVA-challenged mice was
seen (Figure 4c). Hybridization of the antisense and
sense probes in the saline-challenged lung was com-
parable with background (Figure 4d and data not
shown). There was a specific staining of the antisense
probe to a subpopulation of large mononuclear cells
with abundant cytoplasm (within the inflammatory
infiltrates), most consistent with macrophages (Fig-
ure 4, e and f, and data not shown). In addition to
analyzing the cellular distribution of arginase I
mRNA+ cells in the asthmatic lung, we were also inter-
ested in examining arginase expression by immuno-
histochemistry. Anti–arginase I immunohistochem-
istry revealed a very similar pattern of staining
compared with the in situ hybridization studies.
Specifically, the majority of staining was present in
peribronchial and perivascular pockets of inflamma-
tion. Cells with the typical morphology of alveolar
macrophages stained positive for arginase I protein
(Figure 4g). Notably, saline control animals had unde-
tectable arginase protein expression (data not shown).
Finally, staining of allergen-challenged lungs with the
macrophage marker Mac-3 revealed a similar pattern
to arginase I expression (data not shown).
Collectively, these results challenge current para-
digms about arginine metabolism in asthmatic
responses that have previously focused on production
of NO (37). We propose that arginine is metabolized
by arginase, at least in part, in the asthmatic mouse
lung. Furthermore, the variable levels of NO seen in
asthma may be an indirect manifestation of arginase
activity, an enzyme that functionally inhibits NOS by
substrate depletion (12, 13). This model is consistent
with the caution that has been advised with analysis
of expired NO measurements in asthmatics (38).
Lung arginase is regulated by Th2 cytokines. Because asth-
ma is a Th2-associated process and because IL-4 has
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Figure 4
Arginase I mRNA in situ hybridization. The hybridization signal of the
arginase I antisense (AS) and sense (S) probes are shown for
OVA/alum sensitized mice challenged with two doses of OVA (a–c, e)
or saline (d). Tissue was analyzed 18 hours after the second saline or
allergen challenge. Bright field (b, e, f) and dark field images (a, c, d)
are shown at 100 × (a–d) and 400 × (e, f) original magnification. The
dark field signal is white/pink and the bright field signal is black. In the
paired dark and bright field photomicrographs (a and b), a peribron-
chial staining pattern is shown. The hybridization of the AS probe to a
subpopulation of isolated inflammatory cells is shown in e. Staining
was also observed in isolated large mononuclear cells with abundant
cytoplasm, typical for airway macrophages. Examples of such cells
stained by in situ (f) and immunohistochemistry against arginase I (g)
are shown. Arrows indicate representative positive signal. Representa-
tive photomicrographs of four separate mice are shown.
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been shown to induce arginase in several cell lines in
vitro (e.g., macrophages, smooth muscle cells) (23, 39),
we were interested in testing the hypothesis that over-
expression of IL-4, particularly in the lungs, was suffi-
cient for induction of arginase. Mice that overexpress
the IL-4 transgene in pulmonary epithelium (under the
control of the Clara cell 10 promoter) have several fea-
tures of asthma, including eosinophil-rich inflamma-
tory cell infiltrates, mucus production, changes in base-
line airway tone (18), and possibly AHR (data not
shown). We hypothesized that arginase mRNA would
be induced by the IL-4 transgene. Indeed, IL-4 lung
transgenic mice had a marked increase in the level of
both arginase isoforms (Figure 5a).
IL-4 and IL-13 share similar signaling requirements
such as utilization of the IL-4Rα chain and the induc-
tion of janus kinase 1 and STAT6. A subset of their
responses has been shown to be STAT6 dependent (19,
40). To test the role of STAT6 in the induction of
arginase I in vivo, we examined IL-4 lung transgenic
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Figure 5
Regulation of arginase by IL-4, IL-13, and STAT6. Northern blot analyses of arginase I and arginase II in IL-4 lung transgenic mice (in the Balb/c
background) containing either the wild-type or deleted STAT6 gene (a) and lungs from Balb/c mice treated with IL-13 intranasally (c) are
shown. The position of the 18S RNA is shown. Each lane represents a separate mouse. EtBr staining of the RNA gels is also shown. In b, arginase
activity in the lungs of saline- and OVA-challenged (n = 4 and n = 3, respectively) wild-type (WT) and STAT6-deficient (STAT6-KO, n = 4 each)
mice is shown. Arginase activity was measured in lung lysates with the use of the blood urea nitrogen reagent. In d, a kinetic characterization
of IL-13 induced arginase mRNA levels in the lung is shown. Mice (n = 4–10 per group) received one dose of intratracheal IL-13 (10 µg) or PBS.
Lung RNA was converted to cDNA and used for PCR analysis of arginase I (Arg I), arginase II (Arg II), or control hypoxanthine phosphoribo-
syltransferase (HPRT). The lane labeled “control” does not contain cDNA template.
Downloaded from http://www.jci.org on January 21, 2016.   http://dx.doi.org/10.1172/JCI17912
mice that contained wild-type or gene-targeted STAT6.
As shown in Figure 5a, whereas IL-4 lung transgenic
mice contained abundant arginase I mRNA, in the
absence of STAT6, there was a complete loss of the 
IL-4–induced arginase I mRNA. Interestingly, the IL-4
transgene-induced arginase II mRNA signal was only
partially attenuated (if at all) in STAT6-deficient mice
(Figure 5a), indicating that arginase II, in contrast to
arginase I, was largely STAT6 independent. These find-
ings support in vitro studies that have demonstrated
shared and distinct signaling requirements for these
two isoenzymes (12). We were next interested in deter-
mining whether allergen-induced arginase was depend-
ent on STAT6. This would determine whether allergen-
induced arginase was predominantly downstream from
IL-4 and IL-13 signaling. Notably, mice deficient in
STAT6 had a 90% reduction in OVA-induced lung
arginase activity (Figure 5b), suggesting that arginase I
was the predominant inducible isoform in the asth-
matic lung. Northern blot analysis indicated that both
OVA- and Aspergillus-induced arginase I mRNA were
STAT6 dependent (data not shown). Taken together,
these findings indicate that induction of arginase dur-
ing allergic lung inflammation is largely downstream
from IL-4, IL-13, and STAT6. These results are consis-
tent with the recent finding that IL-4 and IL-13 inhib-
it NO production in macrophages by a STAT6-depend-
ent pathway (41). Consistent with these findings, the
murine arginase I promoter contains a single STAT6
site that is required for response to IL-4 (12).
We were next interested in determining whether
lung arginase was also induced by IL-13, a cytokine
that has been shown to be critically involved in the
development of several features of asthma (10, 42),
and to induce arginase in cell lines in vitro (23, 41).
To test this hypothesis, we administered IL-13 by
repeated intranasal application to anesthetized mice.
This protocol induces several features of experimen-
tal asthma, including eosinophilic inflammation,
chemokine induction, mucus production, and AHR
(21, 42). IL-13 administration induced marked levels
of arginase I compared with saline-treated control
mice (Figure 5c). Consistent with the finding that 
IL-4 transgenic mice had elevated levels of arginase II
mRNA, IL-13 also increased arginase II mRNA levels
(Figure 5c). To further analyze the ability of IL-13 to
induce arginase, we treated a murine macrophage cell
line (J774A.1) with IL-13 in vitro. Indeed, IL-13
induced arginase activity in a dose-dependent (0.5–50
ng/mL) manner (data not shown).
We have previously reported that one dose of intra-
tracheal IL-13 induces marked AHR within 12 hours.
We were therefore interested in performing a kinetic
analysis of IL-13 induction of arginase. Notably, after
only one dose of IL-13, the mRNA for the type I iso-
form was found to be induced already by 12 hours
(Figure 5d); the type II isoform was constitutively pres-
ent and induced to a lesser extent. Induction of
arginase was detectable when early AHR developed
(21). The early induction of arginase and AHR precedes
leukocyte recruitment (21 and data not shown). On the
basis of these results, we speculate that the induction
of AHR by IL-13 may be related to the ability of
arginase to functionally inhibit production of the
bronchodilator NO by substrate depletion (12, 13).
Arginase is induced in human asthma. We were interested
in determining whether our findings in experimental
asthma in mice were applicable to human asthma. To
begin to translate our results into humans, we analyzed
arginase I protein expression in bronchoalveolar lavage
fluid cells from individuals with asthma and control
patients. With the use of immunocytochemistry, there
were a significantly higher number of cells expressing
arginase I in the asthmatic group (Figure 6a). In both
groups, the immunopositive cells were predominantly
mononuclear cells with macrophage morphology. A
small population of immunopositive granulocytes was
present in the asthmatic group (data not shown).
Finally, we performed in situ hybridization on
bronchial biopsy specimens from patients with asthma.
Arginase I mRNA+ cells were strongly detected in the
asthmatic lung but were almost completely unde-
tectable in control individuals (n = 4 asthmatic and 4
control individuals). No signal was seen with the con-
trol sense probe (data not shown). Similar to the results
with the mouse models, staining was observed in sub-
mucosal inflammatory cell infiltrates (Figure 6b).
Interestingly, we also observed staining for arginase I
mRNA in epithelial cells (Figure 6b).
Discussion
We have carried out DNA microarray profile analysis
of mice undergoing experimental asthma. By using
two established models of experimental asthma, we
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Figure 6
Arginase I protein expression in human asthma. Fiberoptic bron-
choscopy of allergic asthmatics and healthy controls was conducted,
and BALF was analyzed for arginase I by immunohistochemistry (a).
The number of immunopositive cells, expressed as a percentage of
total cells, is shown. In b, a representative dark field illumination (blue
filter, 200× original magnification) of arginase I mRNA in situ
hybridization of cryostat section from an asthmatic biopsy specimen
by using a S35-labeled RNA probe is shown. Signal was detected most-
ly in the inflammatory cells in the mucosa (arrow). Patchy mRNA pos-
itive cells were also detected within the epithelium (arrowheads).
These results are representative of four asthmatic individuals.
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identified genes that were significantly dysregulated in
the allergic response. Our data show that 6.5% of the
tested genome was dysregulated during induction of
experimental asthma. We demonstrate that the major-
ity of induced genes were similar between the two aller-
gen-challenged models, implicating common path-
ways and allowing us to define a set of asthma
signature genes. At the same time, we report that a
large subset of the identified genome is specific to each
experimental model, indicating significant genetic
diversity despite similar apparent asthma phenotypes.
These data have significant medical implications
because they suggest that clinically similar patients
may have large differences in molecular pathogenesis
of their individual disease. As such, DNA transcript
profiling may eventually provide greater predictive
value than present phenotypic markers (e.g., degree of
eosinophilia, AHR, or histopathology).
We were struck by the finding that the gene for
arginase I was reproducibly present among the aller-
gen-induced genes. In addition, the genes for arginase
II and the L-arginine transporter, CAT2, were increased,
providing further evidence for an important role for
arginine metabolism in allergic airway responses. On
the basis of the potential importance of L-arginine
metabolism via arginase in the pathogenesis of asthma,
and the association of arginase with in vitro Th2
responses, we focused our attention on the regulation
and role of arginase in experimental asthma. In situ
mRNA hybridization analysis of the lung from asth-
matic mice revealed marked induction of arginase I
mRNA in the peribronchial and perivascular inflam-
matory sites with staining in multiple cell types, espe-
cially macrophages. In addition, arginase expression in
the lung was induced by IL-4 and IL-13 in a STAT6-
dependent manner. Although numerous factors may
influence gene expression (e.g., technical procedures,
adjuvants, and routes of antigen administration), our
data indicate that the arginase pathway is not depend-
ent on these factors because arginase is induced by
both asthma models and by Th2 cytokine overexpres-
sion (by pharmacologic and transgenic delivery). These
findings are supported by the recent observation that
NOS and arginase are differentially regulated during
Th1- and Th2-associated granulomatous responses in
mice, respectively (43). Finally, we demonstrate that
arginase is induced in human asthma supporting the
importance of this pathway in human disease. Inter-
estingly, in situ hybridization in the human asthmatic
lung revealed expression in submucosal inflammatory
cells and also airway epithelium, further extending our
findings from the mouse. Notably, airway epithelium
is a major location of arginine and polyamines in the
asthmatic lung (36, 44).
We propose that arginase induction by IL-4/IL-13
signaling is not just a marker of allergic airway
responses, but that arginase is involved in the patho-
genesis of multiple aspects of asthma. Previous stud-
ies have demonstrated the involvement of arginine
metabolism pathways in asthma, but these studies
have primarily focused on metabolism by NOS. Our
study is the first to demonstrate the involvement of
arginase and the arginine transporter, CAT2. Our
demonstration that CAT2 is overexpressed is consis-
tent with reports of the elevated levels of arginine and
nitrotyrosine in airway epithelial cells of asthmatic
subjects (44, 45). Previous studies have shown that
pharmacologic inhibition of NOS enhances agonist-
induced airway constriction in vitro (46, 47) and in
vivo (46, 48, 49). In addition, in a guinea pig model of
asthma, a specific deficiency of bronchodilating
cNOS-derived NO has been shown to contribute to
AHR (47, 48, 50). It has been suggested that the NO
deficiency associated with experimental asthma is
attributable, at least in part, to the ability of eosinophil
cationic proteins to inhibit L-arginine uptake by
macrophages (51). Our current findings suggest that
the NO deficiency associated with asthma may be
largely mediated by arginase induction. By regulating
the availability of L-arginine for NOS (12), arginase
induction may have an important impact on the
induction of AHR. It is interesting to note that 
IL-13–induced AHR occurs in a time frame that paral-
lels arginase induction, suggesting that the ability of
IL-13 to promote AHR may be directly dependent on
arginase induction. This may be particularly impor-
tant because IL-13 has been recently shown to be a
major effector cytokine in asthma pathogenesis (10,
42). Notably, the mechanism by which IL-13 induces
AHR has been unclear; our results draw attention to
the ability of IL-13 to regulate arginase as a possible
mechanism of AHR. In addition to affecting AHR, we
propose that arginase downstream products (proline
and polyamines) are also involved in asthma patho-
genesis. Indeed, we have found elevated levels of
putrescine in the asthmatic murine lung, and elevated
levels of polyamines have been reported in the serum
of patients with asthma (52), corroborating the pro-
duction of biologically active mediators downstream
from arginase. Interestingly, polyamines have con-
tractile activity on smooth muscle (53, 54), possibly
implicating them in asthma-associated AHR. Poly-
amines are present in multiple cell types in the lung
(including airway epithelium, smooth muscle cells,
and macrophages) (36). The ability of polyamines to
affect multiple processes, including cell survival, cell
proliferation, and mucus production (55, 56), indi-
cates that they may have numerous functions in sever-
al cell types present in the asthmatic lung.
Work from several laboratories has led to the notion
that macrophage-derived arginase has a role in the
recovery of host tissues from inflammation (13). This
effect is not only mediated by competing with NOS 
for L-arginine as a substrate, but also by generating 
L-ornithine for synthesis of proline (12). This may be
particularly important in inflammatory sites charac-
terized by tissue remodeling/repair (such as the asth-
matic airway) because proline often becomes a rate
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limiting substrate for collagen synthesis (57, 58).
Under these conditions, it is believed that extracellu-
lar L-ornithine and proline, secreted from arginase
expressing cells (e.g., macrophages) are transported
into fibroblasts, where they subsequently become
incorporated into collagen (57, 58).
In summary, we have described a pathway (involving
arginine metabolism by arginase) not previously exam-
ined in the context of allergic airway inflammation.
Our results challenge the conventional view that argi-
nine is primarily metabolized by NOS in asthmatic
responses; rather, we propose that significant metabo-
lism occurs by arginase, and that this process has
important ramifications on the manifestations of dis-
ease. As such, this new pathway may represent an
important therapeutic intervention strategy for the
treatment of allergic lung disease.
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